Red Flags Detected
- Departure Of Cmo (new) — Chief Medical Officer resigned, though company states departure is not related to clinical operations and no material impact expected.
LB Pharmaceuticals CMO Anna Eramo resigns, transitions to advisor through September
Filed June 10, 2026 · Period ending June 8, 2026 · ~1 min read
Key Changes
-
medium
Chief Medical Officer Dr. Anna Eramo resigned effective June 15, 2026, citing personal reasons. She will provide full-time consulting through September 15, 2026, while the company searches for a replacement.
Item 5.02 verify on EDGAR → -
medium
Company states the departure is unrelated to clinical operations and expects no material impact on development activities or previously disclosed clinical milestones. Experienced teams will continue overseeing ongoing trials.
Item 5.02 verify on EDGAR → -
low
Separation package includes base salary through June 2027, prorated 2026 target bonus at 100%, and acceleration of 66,143 unvested stock options, contingent on completing the three-month consulting period.
Item 5.02 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.
Partner
Trade LBRX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 10, 2026 8:38 PM